Defund NPR Act

Facilitating DIGITAL Applications Act Facilitating the Deployment of Infrastructure with Greater Internet Transactions And Legacy Applications Act

Ensuring Access to Medicaid Buy-in Programs Act

Finn Sawyer Access to Cancer Testing Act This bill provides for coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). Specifically, the bill provides for coverage of microarray analysis, DNA and RNA sequencing, whole-exome sequencing, and other next-generation sequencing for individuals diagnosed with cancer. Additionally, the Department of Health and Human Services must establish an education and awareness program for physicians and the public about genomic testing and the role of genetic counselors.

Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

TREATS Act Telehealth Response for E-prescribing Addiction Therapy Services Act

Wireless Resiliency and Flexible Investment Act of 2025

Sustainable Aviation Fuel Act

SCREEN Act Shielding Children's Retinas from Egregious Exposure on the Net Act

Securing our Radioactive Materials Act

Standing with Moms ActThis bill requires the Department of Health and Human Services (HHS) to disseminate information about pregnancy-related resources, including information about abortion risks and alternatives.Specifically, HHS must create a public website called life.gov that lists such resources that are available through federal, state, and local governments and private entities.Additionally, HHS must create on its existing website a portal that provides a user, based on the user's responses to a series of questions, tailored information about pregnancy resources available in the user's zip code and risks related to abortion. HHS must develop a plan to conduct follow-up outreach to users of the portal (if the user consents to the outreach). States must recommend resources that meet criteria set by HHS for inclusion in the portal. HHS may award grants to states to establish or support a system that aggregates resources to include in the portal.Further, the Health Resources and Services Administration must share information about the new website and portal through the National Maternal Mental Health Hotline.HHS must also ensure that the new website and hotline are available to families who speak languages other than English.The new website, portal, and hotline may not include resources provided by entities that (1) perform, induce, refer for, or counsel in favor of abortions; or (2) financially support such entities.The bill also requires HHS to report on traffic to the new website and portal, gaps in services available to pregnant and postpartum individuals, and related matters.

Spectrum Pipeline Act of 2025

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

Maximizing Israel-U.S. Research Advancement and Collaborative Leadership in Emerging Medical Technology Act of 2025 or the MIRACLE Medical Technology Act of 2025This bill requires the Department of Health and Human Services (HHS) to implement a program for the United States and Israel to collaborate on developing and delivering health care products and services. The program must include coordinated activities in specified areas, including research and development, use of innovative technology, intellectual property protection, regulatory harmonization, disease prevention, and biological product manufacturing. The bill authorizes HHS to establish a joint United States-Israel Health Care Collaboration Center in the United States to leverage existing expertise for advancing the program’s purposes.

Voluntary Sustainable Apparel Labeling Act